Overview

A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants

Status:
COMPLETED
Trial end date:
2025-05-03
Target enrollment:
Participant gender:
Summary
The main objective of this study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) autoinjector dose compared to vial in healthy participants.
Phase:
PHASE1
Details
Lead Sponsor:
Amgen